Although hematopoietic and immune system show high levels of the cannabinoid receptor CB2, the potential effect of cannabinoids on hematologic malignancies has been poorly determined. Here we have investigated their anti-tumor effect in multiple myeloma (MM). We demonstrate that cannabinoids induce a selective apoptosis in MM cell lines and in primary plasma cells of MM patients, while sparing normal cells from healthy donors, including hematopoietic stem cells. This effect was mediated by caspase activation, mainly caspase-2, and was partially prevented by a pan-caspase inhibitor. Their pro-apoptotic effect was correlated with an increased expression of Bax and Bak, a decrease of Bcl-xL and Mcl-1, a biphasic response of Akt/PKB and an increase in the levels of ceramide in MM cells. Inhibition of ceramide synthesis partially prevented apoptosis, indicating that these sphingolipids play a key role in the pro-apoptotic effect of cannabinoids in MM cells. Remarkably, blockage of the CB2 receptor also inhibited cannabinoid-induced apoptosis. Cannabinoid derivative WIN-55 enhanced the anti-myeloma activity of dexamethasone and melphalan overcoming resistance to melphalan in vitro. Finally, administration of cannabinoid WIN-55 to plasmacytoma-bearing mice significantly suppressed tumor growth in vivo. Together, our data suggest that cannabinoids may be considered as potential therapeutic agents in the treatment of MM.
Multiple myeloma (MM) is the second most frequent hematological malignancy. In recent years, therapeutic improvements brought by immunomodulatory drugs and proteasome inhibitors, among other agents, have allowed remarkable progress in the control of this disease. Nevertheless, it is still considered incurable. 1 Hence, great efforts are being devoted to discover novel drugs in order to improve the currently available therapeutic armamentarium. Cannabinoids are the active components of Cannabis sativa (marijuana). Therapeutic interest on cannabinoids emerged after the discovery of an elaborated endocannabinoid physiological control system in humans, based on cannabinoid receptors (CBs), named CB1 and CB2. 2 Whereas CB1 is extremely abundant in the central nervous system (CNS), CB2 is almost exclusively present in hematopoietic and immune cells, which also express CB1 albeit to a much lesser extent. Some hematopoietic cell subsets display high levels of CB2 particularly B-cells, precursors of plasma cells (PCs). 3 Despite this information, the effect of cannabinoids on the hematopoietic system has been investigated to a much lesser extent than in CNS, and many features of CB2 function and regulation remain poorly characterized.
There is increasing evidence supporting that cannabinoids might be useful in the treatment of diseases such as glaucoma, osteoporosis, multiple sclerosis, pain, cardiovascular and neurodegenerative disorders. 4 Currently, they are being used to mitigate vomiting associated with cancer treatment. 5 One of the most stimulating therapeutic interests in cannabinoid research is their potential anti-tumor activity. 6 In this regard, it has been demonstrated that some cannabinoids inhibit the proliferation of several tumor cells, such as glioma cell lines, both in vitro and in vivo. 7, 8 This effect seems to be mediated by the modulation of several signalling pathways involved in cell proliferation, survival and apoptosis. 9 In addition, increasing evidence suggest that ceramides are involved in cannabinoid-induced apoptosis. [10] [11] [12] The first clinical trials exploring the anti-tumor effect of cannabinoids are being conducted in some solid tumors (NCT02255292) including brain cancer (NCT01654497); other studies have recently been completed in glioma (NCT00314808) and glioblastoma (NCT01812616).
Considering both the previously reported anti-tumor effect of cannabinoids and the high expression of CB2 in hematopoietic cells and particularly B cells, we hypothesized that cannabinoids might have anti-tumor effects on malignant plasma cells and could be good candidates for the treatment of MM. Here, we have studied the effect of several cannabinoids on the proliferation and viability of myeloma plasma cells (MPCs) both in vitro and in vivo.
Material and Methods

Statement of ethics
All research involving human material or animal samples was approved by the Ethical Committee for Clinical Research (CEIC) of the University Hospital Virgen del Roc ıo and was conducted in accordance with the Declaration of Helsinki.
Multiple myeloma cell cultures and patient cells
In vitro studies were conducted using six different human MM cell lines. U266, RPMI8226, hereafter referred to as RPMI, and MM1.S (sensitive to dexamethasone) were purchased from ATCC and U266-LR7 (resistant to melphalan); RPMI8226-LR5 (resistant to melphalan), MM1.R (resistant to dexamethasone) cells were kindly provided by Dr. Enrique Ocio (University Hospital of Salamanca, Spain). For ex vivo assays, we also used human primary cells from healthy donors and from MM patients (Supporting Information Table S1 ). Hematopoietic stem cells, B-and T-lymphocytes were isolated from healthy donors' peripheral blood (PB) by positive immunomagnetic separation using human CD34-, CD19-and CD3-MACS microbeads respectively. MPCs were obtained from patients' bone marrow (BM) with a cell infiltration grade >30% (Supporting Information Table 1 ). Mononuclear fraction from BM was extracted using Ficoll-Paque by density gradient centrifugation and later MPCs were identified using anti-CD138 and they were distinguished from the other cell populations by flow cytometry using a suitable combination of antibodies: anti-human CD64-FITC, CD34-PE, CD56-APC, CD38-APC-H7, and CD45-Pacific Blue antibodies (BD Biosciences, San Jose, CA). All cell lines were cultured in RPMI-1640 supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/ streptomycin as recommended by the supplier. For human primary cells, the FBS concentration was up to 20%.
Drugs and treatments
The cannabinoid agonist WIN-55,212-2 mesylate (hereafter referred to as WIN-55) was purchased from Tocris Bioscience. 
Cell viability analysis
Cell viability analysis was performed by a MTT (3-(4,5-dimethylthiazol-2-yl)22,5-diphenyltetrazolium bromide) assay and flow cytometry as described below. MM cell lines and primary MM cells were exposed to different doses of cannabinoids and viability was assessed at 18, 48 and 72 h. The pretreatments with ceramide synthesis inhibitor, pan-caspases inhibitors, and CBs antagonists were conducted for up to 30 min; afterwards the cells were incubated with the cannabinoid WIN-55 up to 18 h. Cell viability was determined by MTT assays using the Cell Counting Kit-8 (Dojindo, Kumamoto, Japan) according to manufacturer's instructions. Cell viability and cell lysis were also assessed by Annexin V/ 7-AAD by flow cytometry. Cells from patients' BM were analyzed using 7-AAD with a combination of monoclonal antibodies against myeloma-associated antigens (anti-CD56-APC, anti-CD45-Pacific Blue, and anti-CD38-APC-H7 [BD Biosciences]) and antibodies to discriminate the granulomonocytic (anti-CD64-FITC) and lymphocytic (anti-CD45-Pacific Blue) populations. Cells were acquired using FACSCanto II flow cytometer (BD Biosciences) and analyzed with Infinicyt TM Software (Cytognos, Spain).
What's new?
Synthetic cannabinoids may help thwart multiple myeloma, according to new results. The hematopoietic system expresses high levels of the cannabinoid receptor CB2, but it is not known whether cannabinoids can be used to hinder hematologic cancers. In this study, the authors demonstrated that cannabinoids induced apoptosis in multiple myeloma cell lines without harming normal cells, including hematopoietic stem cells. They explored the mechanisms behind this apoptosis boost, showing that caspase activation and ceramide accumulation both play a role. When they treated mice with a cannabinoid compound, they successfully stifled plasmacytoma growth. Thus, cannabinoids could prove a useful therapy for multiple myeloma.
Evaluation of synergism between the cannabinoid WIN-55 and other antimyeloma agents, such as dexamethasone and melphalan, was performed assessing cell viability by MTT assays. The potency of the combination was quantified with the Calcusyn Software (Biosoft, Ferguson, MO), which is based on the Chou Talalay method and calculates a combination index (CI) with the following interpretation: CI > 1: antagonistic effect, CI 5 1: additive effect and CI < 1: synergistic effect.
Western blot and antibodies
The antibodies for caspase-2, 28, 29, active-caspase-3, -pAkt, p-Erk, -p-p38MAPK, -p-JNK, -SPT, CB1 and CB2 receptors came from Abcam, anti-Mcl-1 and -Bcl-xL were from Santa Cruz Biotechnology, anti-PARP was from Cell Signaling Technology, anti-Bax and -Bak were from BD Biosciences. Anti-beta-actin and anti-beta-tubulin were from Sigma-Aldrich. All secondary antibodies HRP-conjugated used were from Jackson ImmunoResearch, and performed on donkeys to avoid potential cross-reactivity when multiple probing was performed.
Western blot extracts were performed after 0, 2, 6, 18 and 24 h. Cells were lysed according to Gilbert et al. (2002) adding 2% ASB-14 (CalbioChem, Beeston, UK) to the isotonic lysis buffer. 15 Protein concentration was determined by Pierce V R Microplate BCA Protein Assay kit-Reducing Agent Compatible (Pierce, Rockford, IL). Samples (15-25 lg/lane) were subjected to SDS/PAGE in pre-cast gels AnykD (Bio Rad, Hercules, CA) and transferred onto PVDF membranes using Trans-Blot V R Turbo TM System (Bio-Rad). The membranes were incubated overnight at 48C with primary antibody in TTBS, later with suitable secondary antibody, and subjected to chemiluminescence detection. With respect to control condition, cells were treated with DMSO (<0.15%) in RPMI 1640 medium from Gibco (Gaithersburg, MD).
Immunofluorescence
Cells treated with cannabinoids for 6 h were collected and placed on slides. Immunofluorescence staining was performed as previously described by Vielhaber et al. 16 using anticeramide as primary antibody. The antibody for ceramide was obtained from Sigma-Aldrich. Secondary antibody conjugated with Alexa-488 was from Abcam. With respect to control condition, cells were treated with DMSO (<0.15%) in RPMI 1640 medium from Gibco (Gaithersburg, MD).
Analysis of mitochondrial transmembrane potential
The loss of mitochondrial transmembrane potential (Dwm) was assessed using TRME according to manufacturer's instructions. Briefly, U266 cell lines were exposed to 50 lM of WIN-55 for 15, 30, 45 and 60 min and then incubated for 20 min at 378C with TMRE that accumulates into active mitochondria. TMRE staining was analyzed at 549/575 nm (Ex/Em) by fluorescent microplate spectrophotometry. As a control to induce loss of Dwm was used CCCP.
MM xenografts
NOD/scid/IL-2R gammae null (NSG) mice were purchased to Charles River (France). Tumor xenografts were induced by subcutaneous injection of 5x10e6 U266 cells mixed with 100 ll of Matrigel (BD Biosciences) in 8-week-old mice. When tumors became palpable (>0.5 cm), mice were randomized into the following groups (10 mice per group): (i) to receive i.p. 5 mg/kg WIN-55,212-2 every 24 h, (ii) 5 mg/kg WIN-55,212-2 every 48 h, and (iii) vehicle. As a negative control we used two additional groups of animals which were left tumor-free and inoculated with 100 ll of Matrigel. They received the drug every 24 or 48 h, respectively. Tumor growth was assessed every day measuring two bisecting diameters with calipers. The volume was calculated using the formula (length) 3 (width) e2 3 0.4 mm 3 . Animals were sacrificed when the tumor length or width reached 2 cm.
Statistics
Unless stated otherwise, one representative experiment out of at least three independent experiments is shown. For all statistical analysis, the data were analyzed by Student's t-test with a statistical significance defined as p 0.05. The means and standard deviations were also determined. Synergism was calculated using R as described by Calcusyn software. A combination Index (CI) <1 indicates synergism and >1 antagonism.
Results
Cannabinoids selectively decrease MM cells' viability
Firstly, we assessed the effect of different cannabinoids on the viability of several MM cell lines by MTT assay and flow cytometry. We found that incubation with WIN-55 significantly reduced the viability of all MM cell lines as compared to untreated control cells at 18 h (Fig. 1) . The sensitivity pattern ( Fig. 1a and Table 1 ) ranged from IC50 values between 17.24 and 11.66 lM in U266 and RPMI, respectively. We also confirmed this effect by flow cytometry for U266 and RPMI (Fig. 1b) at 18 h and at 48 and 72 h (Supporting Information Figure 1S ). In addition, all MM cell lines were treated with four different cannabinoid derivatives, PGN-6, 217, 234, and 272, which are characterized by their higher selectivity for CB2 receptor as compared to WIN-55. As shown in Figure 1c , these PGN cannabinoids also induced a significant decrease in the viability of MM cell lines.
The effect of cannabinoids was further examined ex vivo by flow cytometry in MPCs obtained from six MM patients (Supporting Information Table S1 ) using WIN-55. After treatment, MPCs viability showed a remarkable decrease of 85% at 50 lM (Figs. 1d and 1e) . By contrast, viability of the normal cell subpopulations from healthy donors was hardly affected. Only the highest dose tested induced an anti-proliferative effect on lymphocytes. When we analyzed the viability of T or B-lymphocytes separately, we observed that only B-cells viability was reduced whereas T-cells were unaffected after treatment with WIN-55 (Fig. 1e) . However, PGN-6 and 217 cannabinoids did not affect either B-or T-cells viability, even at doses of 100 lM (Fig. 1e) . Finally, we tested the effect of WIN-55 on hematopoietic stem cells (CD341) from healthy donors and the residual normal CD341 cell populations from MM patients. Strikingly, the hematopoietic stem cells viability remained unaffected upon cannabinoid treatment even at the highest dose tested (Fig. 1e) . These results indicate that cannabinoids have a selective pro-apoptotic effect on myelomatous plasma cells, whereas viability of normal healthy cells, including hematopoietic precursor cells, remains unaffected.
The effect of cannabinoids is mediated by apoptotic mechanisms. To assess whether the effect of WIN-55 is mediated by apoptotic mechanisms, we analyzed the expression of PARP, caspases and Bcl-2 family proteins in the most resistant MM cell line, U266. Cannabinoid treatment induced fragmentation of PARP in a time-dependent manner (Fig. 2a) . Furthermore, we observed an increase over time in the expression of the active cleaved forms of caspase-3, 17 kDa and 12 kDa (Fig. 2a) , consistent with an induction of caspases activation. Regarding the expression of the main initiator caspases, this is, caspase-9, 28 and 22, we observed a decrease in the pro-caspase forms after cannabinoid exposure. The higher increase in cleaved forms was detected for caspase-2, which displayed a remarkable activation compared to caspase-8 and 29 (Fig. 2b) . To confirm that the pro-apoptotic effect is caspase-dependent we co-incubated WIN-55 treated cells with or without the pan-caspase inhibitor Z-VAD-FMK. As shown in Figure 2c , the pan-caspase inhibitor prevented cannabinoid-induced apoptosis in both the most resistant and the most sensitive cell lines, i.e. U266 and RPMI. Next, we analyzed the expression of several proteins of Bcl-2 family, such as Mcl-1, Bcl-xL, Bax and Bak. We observed a remarkable increase of the pro-apototic proteins Bak and Bax, while that expression of the anti-apoptotic proteins, Bcl-xL and Mcl-1, decreased over time (Fig. 2d) . These results show that the effect of cannabinoids in MM cells is at least in part mediated by apoptotic mechanisms, the caspase-2 pathway being the most strongly activated.
Signaling pathways targeted by cannabinoids in myelomatous cells. In order to explore the signaling pathways implicated in cannabinoid-induced apoptosis, we also assessed the expression profile of phosphorylated-JNK, -Erk1/2, -p38-MAPK and -Akt. Cannabinoid treatment slightly upregulated p-JNK and p-Erk1/2 whereas moderately downregulated p-p38-MAPK over time. Intriguingly, Akt is the most strongly modulated pathway by cannabinoids and displayed a biphasic response, with a short-term activation and a long-term downregulation (Fig. 2e) .
De novo synthesis of ceramides is involved in cannabinoidinduced apoptosis. It is known that ceramide is a powerful suppressor potentiating and driving the process of apoptosis. 17 Given that accumulation of de novo-synthetized ceramides has been implicated in the pro-apoptotic effect of cannabinoids in glioma cells, [10] [11] [12] we evaluated whether or not ceramide is also involved in the pro-apoptotic effect of cannabinoids in myeloma. Thus, we evaluated ceramide expression and analyzed by Western blot the expression of serine-palmitoyltransferase (SPT), the rate-limiting enzyme in de novo ceramide synthesis. We observed that cannabinoid treatment induced a remarkable increase in ceramide immunolabeling in U266 cells as compared to untreated cells (Fig. 3a) . Furthermore, the expression of (SPT) increased over time in U266 treated cells (Fig. 3b) . To confirm the ceramide involvement in the cannabinoid-induced apoptosis, MM cells were pre-incubated with Fumonisin B1, an inhibitor of ceramide synthesis. This pharmacological blockage of ceramide synthesis notably prevented the PARP fragmentation induced by WIN-55 in U266 cells (Fig. 3c ) and significantly reversed the pro-apoptotic effect induced by this cannabinoid in both U266 and RPMI (Fig. 3d) . These data confirmed that ceramide plays a key role in the cannabinoidinduced apoptosis in MM cells.
Effect of cannabinoids in endoplasmic reticulum (ER) and mitochondria. Since myelomatous cells have a remarkably developed ER, they are prone to ER-stress. Thus, we evaluated the cannabinoid effect of ER-stress in U226 cells. Contrary to our expectations, we found a slightly but sustained decrease in the expression of ER-stress protein markers CHOP, ATF-4, p-IRE1 and XBP-1 sec, in comparison with control cells, and a slight increase in XBP-1u level in cannabinoid-treated cells as compared to control cells. This observation might suggest that cannabinoids diminish or, at least, do not overload the unfolded-protein response (UPR) in MM cells (Fig. 4a) .
Since the loss of Dwm is a no-return point in the apoptosis, we tested the changes on Dwm in cannabinoid-treated U266 cells. We observed a remarkable decay of Dwm as early as 15 min of incubation, which continued slightly decreasing over time (Fig. 4b) .
The effect of cannabinoids on MM cells is mediated through CB2 receptor. To know whether the pro-apoptotic effect of WIN-55 is mediated through CB2 receptor, we assessed the effect of WIN-55 after treatment with different selective CB2-antagonists, PGN-8, 237 and 270. Pre-incubation with all these CB2-antagonists remarkably inhibited the pro-apoptotic effect induced by WIN-55 in both U266 and RPMI cell lines (Fig. 4c) , confirming that the effect of WIN-55 is mediated through CB2. 
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Later we evaluated the expression of CB2 in different MM cell lines as well as in normal hematopoietic cells. We observed a heterogeneous pattern on the various cell subtypes. CB2 mainly exhibited a band at 40 kDa, consistent with the weight of the monomer-CB2, and another band at 30 kDa corresponding to a truncated form. The higher levels of CB2 were detected in the most sensitive cell lines, such as MM1.R and RPMI as well as in lymphocytes, whereas it was hardly immunoreactive in the most resistant cell lines and in hematopoietic stem cells (Fig. 4d) .
WIN-55 potentiates the effect of other anti-myeloma agents.
Afterwards, we analyzed the cannabinoid effect in double combinations with dexamethasone and melphalan, in U266, RPMI U266-LR7 and RPMI-LR5 cell lines. The combination index (CI) obtained indicated that WIN-55 was synergistic with both dexamethasone and melphalan, even in the melphalan-resistant cell lines (Figs. 5a and 5b) . The dose of WIN-55 used was suboptimal according to IC50 for each cell line, namely 20uM for U266, U266-LR7 and RPMI-LR5 and 10uM for RPMI. Our results indicate that WIN-55 in combination with dexamethasone or melphalan not only acts synergistically, but also overcomes resistance of MM cell lines. The administration of cannabinoids inhibits tumor growth in vivo. Finally, we analyzed the anti-tumor effect of the cannabinoids in vivo, using a preclinical model of human MM xenograft in the immunodeficient NOD/SCID mice (NSG). For this purpose, we used U266, the most resistant MM cell line in vitro. We observed a remarkable and progressive loss of tumor-volume following cannabinoid administration as compared to vehicle-treated counterparts (Fig. 6 ).
Discussion
Within the oncology field, the cannabinoid research has mainly focused on their anti-emetic effect, whereas their anti-neoplastic properties were not addressed until the late 1990s, and has mainly focused on solid tumors such as glioma 18 and breast cancer. 19 Regarding hematologic malignancies, little information is available. Specifically in MM, Morelli et al. 20 analyzed the effect of cannabidiol in two MM cell lines induced to express the transient receptor potential vanilloid type-2 (TRPV2) and in primary cells selected based on the expression of TRPV2. The authors describe that cannabidiol exerts a pro-apoptotic effect at least partially mediated by this induced TRPV2 receptor. Given that U266 and RPMI cell lines do not express the receptor TRPV2, we suggest that the effect of WIN-55 on myelomatous cells would not be mediated by this vanilloid receptor. For their part, Feng et al. 21 studied the effect of a cannabinoid receptor antagonist, namely phenylacetylamide, and they showed that this drug induces cell cycle arrest in MM cell lines.
In the current study, we show that different cannabinoid derivatives reduce MM cells viability, including both cell lines and primary MPCs from high-risk MM patients and that, moreover, this effect was very selective, since the viability of normal healthy cells including hematopoietic stem cells remained unaffected.
This pro-apoptotic effect is at least in part caspase-dependent, caspase-2 playing a dominant role in the cannabinoid-induced apoptosis in MM cells. [22] [23] [24] Activation of caspase-2 upstream of caspase-9 has been described in MM cells after treatment with bortezomib. 25 This agent exerts its pro-apoptotic effect increasing ER-stress. A similar effect has been reported in glioma cell lines treated with cannabinoids. 26 Unexpectedly, our results show that cannabinoids reduce the activation of UPR. It could be considered that these drugs might decrease the ability of the MM cells to compensate their basal ER-stress, impairing their ability to use the cytoprotective role of the UPR. 27 More precisely, de novo synthesis of ceramide occurs in the ER 28 playing a pivotal role in apoptosis. 29, 30 Cannabinoids can promote ceramide synthesis by both sphingomyelin hydrolysis and de novo pathway. But only de novo synthesis has been linked to the apoptotic effect of cannabinoids. Remarkably, the activity of this pathway is regulated by the SPT enzyme. 10 We found that exposure to cannabinoids upregulates SPT, increasing the levels of ceramides. In fact, blockage of ceramide synthesis confirmed the involvement of ceramide in cannabinoid-induced apoptosis. 31, 32 This fact might be related to the non-extenuation of ER-function, thus allowing the ceramide synthesis in the ER. In addition, we detected an early Dwm in treated-MM cells, which occurs even before the cleavage of caspases. In line with our results, it has been described that ceramide can move from ER to mitochondria, rapidly permeabilizing the membrane, even before and independently of caspases activation. [33] [34] [35] Besides, we observed an early upregulation of Bax and Bak, which are implicated in the stabilization of mitochondrial ceramide-channels. [36] [37] [38] [39] Ceramide also promotes inhibition of Mcl-1 and Bcl-xL, 40 matching with the downregulation of both Mcl-1-and Bcl-x that we have observed.
Akt is the most strongly activated signaling pathway by cannabinoids in MM cells, inducing a biphasic response similar to the cannabinoid-induced response reported in gliomas. 41 This inhibition of Akt is in line with previous observations reported using other cannabinoid derivatives in other tumors such as melanoma and breast cancer, and suggests that the apoptotic effect of cannabinoids also relies on Akt inhibition, [10] [11] [12] 41 Concerning MAPKs pathways and given the low magnitude of regulation observed in this study, we suggest that it merely might be a consequence of crosstalk between pathways.
In addition, blockade of the WIN-55-induced apoptosis using specific CB2-antagonists indicates that their effect is mediated through CB2. Our results also suggest a correlation between the CB2 expression and the susceptibility to cannabinoids, also described in other tumors. 42 Considering the high expression of CB2 in the hematopoietic system and its low expression in CNS, the selective-CB2 effect might favor a low toxicity prolife. Nevertheless, further research will be required in order to shed more light on how these drugs exert a pro-apoptotic effect in tumor cells versus their non-transformed counterpart.
Finally, in the current study we provide the first evidence of a successful in vivo treatment with cannabinoids in a Figure 6 . WIN-55 considerably inhibits tumor growth in NSG mice in vivo. 5 3 10 6 U266 cells were subcutaneously inoculated in the inter-scapular flank and mice (10 mice per group) were randomized into three groups to receive i.p. 5 mg/kg WIN-55,212-2 every 24 h, every 48 h, and vehicle (<0.15% DMSO in medium) as positive control group. Tumor diameters were measured every other day and the volume estimated as the ellipse volume. Graphic shows the evolution of tumor volume for the indicated days. Statistical significance was defined as p 0.05 and asterisk indicates the first day in which differences were statistically significant for each dose. Data represent mean 6 SD of volume of all mice in each group. murine xenograft model of MM. U266 cell line, being the most resistant cell line in vitro, was selected to perform in vivo studies. Even so, WIN-55 induced an impressive tumor growth inhibition and did not produce overt toxicity. In fact, a recent study about the anti-epileptic activity of WIN-55 conducted in mice demonstrated that, at the same doses used in our study (5 mg/kg), it did not induce adverse effects with regards to motor coordination or learning. 43 In conclusion, in the current study we describe the antimyeloma effect of cannabinoids. These drugs show a remarkable and selective pro-apoptotic effect on myelomatous cells while sparing the healthy counterpart cells. Cannabinoidinduced apoptosis is CB2 mediated and involves the cooperation of different mechanisms, highlighting the implication of ceramide and caspase-2. This study lays the groundwork for the design of new anti-myeloma therapies.
